Atanis Biotech recently had the privilege of participating in the Congressional Food Allergy Research Caucus briefing on Capitol Hill - a gathering that brought together policymakers, researchers, and advocates around a shared and urgent mission: improving the lives of millions affected by food allergies.
Food allergies are no longer a niche concern. They represent a growing public health challenge, impacting over 30% of the global population and rising steadily over the past decades . In the United States alone, millions of patients, including children at risk of life-threatening reactions, face daily uncertainty due to limitations in current diagnostic tools and treatment pathways.
What made this briefing particularly meaningful was the clear shift in tone: the conversation is moving beyond awareness and into action.
A Turning Point in Food Allergy Science
For years, food allergy diagnosis has relied on a combination of methods that are often incomplete, inconvenient, or even risky. Traditional tests such as skin prick testing and specific IgE measurements can lack specificity, while oral food challenges, considered the gold standard, are time-consuming and carry real clinical risks .
Today, however, scientific innovation is beginning to close this gap.
Emerging diagnostic technologies are enabling a more precise understanding of allergic reactions at a biological level, helping clinicians move beyond probability-based assessments toward functional, patient-specific insights. This shift opens the door to:
- Earlier and more accurate diagnoses
- Better risk stratification for patients
- More informed treatment decisions
- Improved monitoring of therapy over time
Atanis Biotech is at the forefront of this transformation. Our proprietary FAST-PASEĀ® platform is designed to replicate allergic reactions in vitro, offering a safe, accurate, and highly predictive alternative to traditional approaches .
Bridging Science and Policy
Engaging directly with members of Congress provided a valuable opportunity to highlight whatās coming next for patients and what is needed to accelerate progress.
Key themes discussed during the briefing included:
- The importance of advancing diagnostic standards to reduce misdiagnosis and unnecessary risk
- The need for regulatory pathways that support innovation while maintaining patient safety
- Expanding access to next-generation diagnostics and treatments
- Supporting continued research in allergy and immunology
These conversations are critical. Scientific breakthroughs alone are not enough, they must be matched by policy frameworks that enable adoption and access at scale.
Atanisā Commitment to the Future of Allergy Care
Representing Atanis Biotech in this setting underscores our broader mission: to redefine how allergies are diagnosed, understood, and managed.
We believe the future of allergy care will be:
- More precise - grounded in functional biology rather than indirect markers
- Safer - minimizing patient exposure to unnecessary risks
- Faster - reducing the time from symptoms to actionable answers
- Actionable - empowering both patients and providers with meaningful insights
The momentum we witnessed on Capitol Hill reflects a broader alignment across science, policy, and patient advocacy. It is a signal that the field is ready for change and that change is already underway.
We are proud to contribute to this progress and remain committed to working alongside partners across the ecosystem to bring better diagnostics and better outcomes to patients worldwide.
